How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Description:
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-DOTAM-MAM279, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Sponsor:
Molecular Partners AG
Contacts:
Medical Director MPAGinfo@molecularpartners.com
+41 44 755 77 00
Government Study Link:
NCT07278479 - Click here to see study onClinicalTrials.gov
[212Pb]Pb-DOTAM-MAM279
Isotope(s):
Target(s):
- DLL3
Isotope(s):
Target(s):
- DLL3
